Oncology

DelveInsight, the leading market research and consulting company has added a new report “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” to its portfolio. The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions. It comprehensively includes: Information on 215+ products and 50+ different technologies along with 70+ companies actively involved in drug development. There are 5 drugs in phase III, 22 in phase II, 42 in phase I, an...